# Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

> **NCT01231607** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 917 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** 1mg Finasteride active
- **DRUG:** 0.02mg dutasteride
- **DRUG:** 0.1mg dutasteride
- **DRUG:** 0.5mg dutasteride
- **DRUG:** Finasteride placebo
- **DRUG:** Dutasteride placebo

## Key facts

- **NCT ID:** NCT01231607
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-28
- **Primary completion:** 2012-02-01
- **Final completion:** 2012-02-28
- **Target enrollment:** 917 (ACTUAL)
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231607, "Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01231607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*